ECSP13012629A - COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3 - Google Patents

COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3

Info

Publication number
ECSP13012629A
ECSP13012629A ECSP13012629A ECSP13012629A EC SP13012629 A ECSP13012629 A EC SP13012629A EC SP13012629 A ECSP13012629 A EC SP13012629A EC SP13012629 A ECSP13012629 A EC SP13012629A
Authority
EC
Ecuador
Prior art keywords
phenylsulphanylme
mglur
antagonists
hexane
substituted
Prior art date
Application number
Other languages
English (en)
Inventor
Charles Howard Mitch
Renhua Li
Stephon Cornell Smith
Tatiana Natali Vetman
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45099188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP13012629(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP13012629A publication Critical patent/ECSP13012629A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/18—All rings being cycloaliphatic the ring system containing six carbon atoms

Abstract

La presente invención se refiere a un antagonista del receptor mGlu2/3 de la fórmula:se describen sus usos, y métodos para su preparación.
ECSP13012629 2010-11-18 2013-05-17 COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3 ECSP13012629A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41512110P 2010-11-18 2010-11-18

Publications (1)

Publication Number Publication Date
ECSP13012629A true ECSP13012629A (es) 2013-07-31

Family

ID=45099188

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP13012629 ECSP13012629A (es) 2010-11-18 2013-05-17 COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR 2/3

Country Status (36)

Country Link
US (1) US8629169B2 (es)
EP (1) EP2640697B1 (es)
JP (1) JP5877847B2 (es)
KR (2) KR20150140876A (es)
CN (1) CN103228625B (es)
AR (1) AR083845A1 (es)
AU (1) AU2011329076B2 (es)
BR (1) BR112013012118A2 (es)
CA (1) CA2818116C (es)
CL (1) CL2013001345A1 (es)
CO (1) CO6761385A2 (es)
CR (1) CR20130178A (es)
DK (1) DK2640697T3 (es)
DO (1) DOP2013000099A (es)
EA (1) EA021724B1 (es)
EC (1) ECSP13012629A (es)
ES (1) ES2650139T3 (es)
GT (1) GT201300126A (es)
HR (1) HRP20171649T1 (es)
HU (1) HUE037457T2 (es)
IL (1) IL225843A (es)
LT (1) LT2640697T (es)
MA (1) MA34663B1 (es)
MX (1) MX339973B (es)
NO (1) NO2640697T3 (es)
NZ (1) NZ609816A (es)
PE (1) PE20140997A1 (es)
PL (1) PL2640697T3 (es)
PT (1) PT2640697T (es)
RS (1) RS56535B1 (es)
SG (1) SG189959A1 (es)
SI (1) SI2640697T1 (es)
TW (1) TWI520935B (es)
UA (1) UA110039C2 (es)
WO (1) WO2012068067A1 (es)
ZA (1) ZA201302918B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2978B1 (en) * 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids
EP3000814A1 (en) 2014-09-26 2016-03-30 Domain Therapeutics Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
DK3445743T3 (da) 2016-04-18 2021-10-18 Taisho Pharmaceutical Co Ltd Prodrug af aminosyrederivat
JP2020506895A (ja) 2017-01-17 2020-03-05 ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物
US11046649B2 (en) 2018-07-17 2021-06-29 Board Of Regents, The University Of Texas System Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0669928B2 (ja) 1987-10-06 1994-09-07 宇部興産株式会社 光重合性歯科材料
JP2589812B2 (ja) 1989-07-05 1997-03-12 松下電器産業株式会社 スチームアイロン
EA000894B1 (ru) * 1995-11-16 2000-06-26 Эли Лилли Энд Компани Замещенные бициклогексанкарбоновые кислоты и их производные в качестве антагонистов рецептора возбуждающих аминокислот, способ их получения и применение
ZA969485B (en) 1995-11-16 1998-05-12 Lilly Co Eli Excitatory amino acid receptor antagonists.
ZA983930B (en) * 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
EP1064256B1 (en) * 1998-03-17 2004-08-04 Pfizer Products Inc. Bicyclo [2.2.1] heptanes and related compounds
GB9815542D0 (en) 1998-07-17 1998-09-16 Lilly Co Eli Bicyclohexane derivatives
CH694053A5 (de) 1998-09-03 2004-06-30 Hoffmann La Roche Verfahren zur Herstellung von 2-Amino-bicyclo[3.1.0]hexan-2,6-dicarbonsäure-Derivaten.
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
AU2002359923B2 (en) 2001-12-27 2007-12-20 Taisho Pharmaceutical Co., Ltd. 6-fluorobicyclo[3.1.0]hexane derivatives
PT1517915E (pt) * 2002-06-11 2009-04-09 Lilly Co Eli Pró-drogas de amino ácidos de excitação
NZ580554A (en) * 2003-06-26 2011-01-28 Taisho Pharmaceutical Co Ltd 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic ester derivative
JP2007063129A (ja) 2003-06-26 2007-03-15 Taisho Pharmaceut Co Ltd ２−アミノ−３−アルコキシビシクロ［３．１．０］ヘキサン誘導体
WO2005000790A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体
JO2978B1 (en) * 2009-12-21 2016-03-15 ايلي ليلي اند كومباني MGLU2 aids

Also Published As

Publication number Publication date
CO6761385A2 (es) 2013-09-30
MA34663B1 (fr) 2013-11-02
DOP2013000099A (es) 2013-08-15
NO2640697T3 (es) 2018-02-17
SG189959A1 (en) 2013-06-28
CR20130178A (es) 2013-07-09
WO2012068067A1 (en) 2012-05-24
TW201307271A (zh) 2013-02-16
TWI520935B (zh) 2016-02-11
SI2640697T1 (sl) 2017-11-30
KR20130101094A (ko) 2013-09-12
EA201390498A1 (ru) 2013-07-30
ZA201302918B (en) 2014-10-29
AU2011329076B2 (en) 2015-03-12
GT201300126A (es) 2014-02-27
IL225843A (en) 2015-05-31
JP2014505664A (ja) 2014-03-06
CA2818116A1 (en) 2012-05-24
RS56535B1 (sr) 2018-02-28
MX339973B (es) 2016-06-20
UA110039C2 (xx) 2015-11-10
CN103228625B (zh) 2014-12-03
AU2011329076A1 (en) 2013-05-02
CA2818116C (en) 2016-04-05
NZ609816A (en) 2014-12-24
HUE037457T2 (hu) 2018-08-28
EA021724B1 (ru) 2015-08-31
JP5877847B2 (ja) 2016-03-08
PT2640697T (pt) 2017-12-11
PL2640697T3 (pl) 2018-02-28
PE20140997A1 (es) 2014-08-25
EP2640697A1 (en) 2013-09-25
US8629169B2 (en) 2014-01-14
KR20150140876A (ko) 2015-12-16
LT2640697T (lt) 2018-01-10
HRP20171649T1 (hr) 2017-12-15
CL2013001345A1 (es) 2013-11-15
ES2650139T3 (es) 2018-01-17
CN103228625A (zh) 2013-07-31
AR083845A1 (es) 2013-03-27
IL225843A0 (en) 2013-06-27
US20120129902A1 (en) 2012-05-24
MX2013005622A (es) 2013-07-05
EP2640697B1 (en) 2017-09-20
DK2640697T3 (en) 2017-10-23
BR112013012118A2 (pt) 2016-09-27

Similar Documents

Publication Publication Date Title
GT201500138A (es) Novedososo derivados de bencimidazol como antagonistas de ep4
DOP2012000135A (es) Compuestos de espiropiperidina como antagonistas del receptor orl-1
CR20150370A (es) Compuestos antivirales
UY35257A (es) Picolinamidas macrocíclicas como fungicidas, composiciones y metodos para el control de enfermedades vegetales
UY33735A (es) Compuestos antivirales
CR20150271A (es) Peptidos como agonistas de oxitocina
EP2721011A4 (en) EP2 RECEPTOR ANTAGONISTS OF PROSTAGLANDINS, DERIVATIVES, COMPOSITIONS AND USES THEREOF
CR20140435A (es) Nuevos derivados de tienopirimidina, procesos para su preparacion y sus usos terapeuticos
DOP2015000113A (es) 6-((s)-1-{1-[5-(2-hidroxi-etoxi)-piridin-2-il]1h-pirazol-3-il}-etil)-3h-1,3-benzotiazol-2-ona como un antagonista del receptor ampa dependiente de tarp-gamma 8
CO6761385A2 (es) Compuestos 3-fenilsulfanilmetil-biciclo[3.1.0]hexano 4-sustituidos como antagonistas de mglur 2/3
GT201200328A (es) Intermedios de agomelatina y método de preparación de éstos
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
HK1207855A1 (en) Substituted carbamate compounds and their use as transient receptor potential (trp) channel antagonists (trp)
CL2015000038A1 (es) Métodos para preparar triazolopiridinas sustituidas y compuestos intermediarios.
MX2013005623A (es) Compuestos de 3-benciloxi-biciclico [3.1.0] hexano 4-sustituidos como antagonistas de mglur 2/3.
UY33409A (es) Moduladores no competitivos de receptores nicotinicos
CR20150028A (es) Derivados de ariletinilo
CR20140531A (es) Derivados de ariletinilo
CU20150015A7 (es) Tris-(hetero)aril-pirazoles y su uso
MX2015005312A (es) Derivados de 1h-indazol-3-carboxamida y uso de los mismos como antagonistas de p2y12.
CR20140130A (es) 2-(croman-6-iloxi)-tiazoles sustituidos y su uso como productos farmacéuticos
UY34489A (es) Derivados del ácido cicloalcanocarboxílico como antagonistas del receptor CXCR3
TN2013000209A1 (en) 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mglur 2/3 antagonists
ES2421810R1 (es) Intermedios utiles para la sintesis de fexofenadina, procedimientos para su preparacion y para la preparacion de fexofenadina
UA54879U (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиоксидантного действия